Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones

Cancer Journal

Volumn 6, Issue SUPPL. 3, 2000, Pages

  Riddell, Stanley R ^a   Warren, Edus H ^a   Gavin, Marc A ^a   Akatsuka, Yoshiki ^a   Lewinsohn, Deborah ^a   Mutimer, Helen ^a   Cooper, Laurence ^a   Topp, Max S ^a   Bonini, Chiara ^a   Greenberg, Philip D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ALLOGRAFT; CONFERENCE PAPER; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOTOXIC T LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; PRIORITY JOURNAL; VIRUS LOAD;

CLONE CELLS; GENETIC TECHNIQUES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 0033914129     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Riddell SR, Rabin M, Geballe AP et al. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991;146:2795-2804.
2. McLaughlin-Taylor E, Pande H, Forman SJ et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-110.
3. Wills MR, Carmichael AJ, Mynard K et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-7579.
4. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-488.
5. Talmadge JE, Reed E, Ino K et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997;19:161-172.
6. Ruutu T, Ljungman P, Brinch L et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplant 1997;19:233-236.
7. Ringden O, Pihlstedt P, Volin L et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1987;2:299-305.
8. Quinnan GV Jr, Kirmani N, Rook AH et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13.
9. Reusser P, Riddell SR, Meyers JD et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-1380.
10. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-1979.
11. Reddehase MJ, Weiland F, Munch K et al. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 1985;55:264-273.
12. Reddehase MJ, Mutter W, Munch K et al. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 1987;61:3102-3108.
13. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241.
14. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
15. Zajac AJ, Blattman JN, Murali-Krishna K et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205-2213.
16. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-8063.
17. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
18. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
19. Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy [editorial; comment]. N Engl J Med 1999;340:1672-1674.
20. Furtado MR, Callaway DS, Phair JP et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
21. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
22. Garcia F, Plana M, Vidal C et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999;13:F79-86.
23. Borrow P, Lewicki H, Hahn BH et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
24. Musey L, Hughes J, Schacker T et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodefciency virus type 1 infection. N Engl J Med 1997;337:1267-1274.
25. Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2106.
26. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
27. Ortiz GM, Nixon DF, Trkola A et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999;104:R13-18.
28. Koup RA. Virus escape from CTL recognition. J Exp Med 1994;180:779-782.
29. Brodie SJ, Lewinsohn DA, Patterson BK et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999;5:34-41.
30. McKinney DM, Lewinsohn DA, Riddell SR, et al. The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. J Immunol 1999;163:861-867.
31. Reddehase MJ, Mutter W, Koszinowski UH. In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med 1987;165:650-656.
32. Nelson BH, Lord JD, Greenberg PD. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature 1994;369:333-336.
33. Evans LS, Witte PR, Feldhaus AL et al. Expression of a chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptor in human cytotoxicT lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. Hum Gene Ther 1999;10:1941-1951.
34. Pitcher CJ, Quittner C, Peterson DM et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-525.
35. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
36. Boon T, Cerottini JC, Van den Eynde B et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
37. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-287.
38. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
39. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
40. Appelbaum FR. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997;24:114-123.
41. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997;157:125-140.
42. Warren EH, Gavin M, Greenberg PD et al. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol 1998;5:429-433.
43. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
44. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
45. de Bueger M, Bakker A, Van Rood JJ et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992;149:1788-1794.
46. Wang W, Meadows LR, den Haan JM et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-1590.
47. Meadows L, Wang W, den Haan JM et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997;6:273-281.
48. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998;91:2197-2207.
49. Warren EH, Gavin M, Simpson E et al. Uty encodes a novel H-Y minor histocompatibility antigen in humans. J Immunol 2000;164:2807-2814.
50. Dolstra H, Fredrix H, Preijers F et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 1997;158:560-565.
51. Dolstra H, Fredrix H, Maas F et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999;189:301-308.
52. den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998;279:1054-1057.
53. van der Harst D, Goulmy E, Falkenburg JH et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994;83:1060-1066.
54. Falkenburg JH, Goselink HM, van der Harst D et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991;174:27-33.
55. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648.
56. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
57. Bonnet D, Warren EH, Greenberg PD et al. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999;96:8639-8644.
58. Gubarev MI, Jenkin JC, Leppert MF et al. Localization to chromosome 22 of a gene encoding a human minor histocompatibility antigen. J Immunol 1996;157:5448-5454.
59. Hunt DF, Henderson RA, Shabanowitz J et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-1263.
60. den Haan JM, Sherman NE, Blokland E et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-1480.
61. Mutis T, Verdijk R, Schrama E et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93:2336-2341.
62. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.